HomeTrialNCT06430385
🔬NCT06430385Phase 1Phase 2RECRUITING

ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)

Study Summary

The primary purpose of this study is to evaluate the safety and tolerability of ION440.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment48 participants
Primary Completion
Lead SponsorIonis Pharmaceuticals, Inc.
Data Retrieved2026-04-11 04:17:53.139422+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.